236 related articles for article (PubMed ID: 6809316)
1. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors.
Neuwelt EA; Hill SA; Frenkel EP; Diehl JT; Maravilla KR; Vu LH; Clark WK; Rapoport SI; Barnett PA; Lewis SE; Ehle AL; Beyer CW
Cancer Treat Rep; 1981; 65 Suppl 2():39-43. PubMed ID: 6809316
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
[TBL] [Abstract][Full Text] [Related]
3. [Intra-arterial chemotherapy of malignant glioma after osmotic blood-brain barrier disruption].
Yamada K; Takahama H; Nakai O; Takanashi T; Hosoya T
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2692-6. PubMed ID: 2506817
[TBL] [Abstract][Full Text] [Related]
4. Blood-brain barrier disruption and methotrexate in the treatment of a readily transplantable intracerebral osteogenic sarcoma of rats.
Cosolo W; Christophidis N
Cancer Res; 1987 Dec; 47(23):6225-8. PubMed ID: 3119195
[TBL] [Abstract][Full Text] [Related]
5. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors.
Neuwelt EA; Rapoport SI
Fed Proc; 1984 Feb; 43(2):214-9. PubMed ID: 6692941
[TBL] [Abstract][Full Text] [Related]
6. Intracarotid infusion of hypertonic mannitol changes permeability of blood-brain barrier to methotrexate in rats.
Pan GY; Liu XD; Liu GQ
Acta Pharmacol Sin; 2000 Jul; 21(7):613-6. PubMed ID: 11360668
[TBL] [Abstract][Full Text] [Related]
7. [ACNU delivery to malignant glioma tissue by osmotic blood brain barrier modification with intracarotid infusion of hyperosmoral mannitol].
Miyagami M; Kagawa Y; Tsubokawa T
No Shinkei Geka; 1985 Sep; 13(9):955-63. PubMed ID: 2999632
[TBL] [Abstract][Full Text] [Related]
8. The effects of magnesium sulfate on blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats.
Kaya M; Gulturk S; Elmas I; Kalayci R; Arican N; Kocyildiz ZC; Kucuk M; Yorulmaz H; Sivas A
Life Sci; 2004 Nov; 76(2):201-12. PubMed ID: 15519365
[TBL] [Abstract][Full Text] [Related]
9. Osmotic blood-brain barrier disruption: a new means of increasing chemotherapeutic agent delivery.
Neuwelt EA; Frenkel EP; Diehl JT; Maravilla KR; Vu LH; Clark WK; Rapoport SI; Barnett PA; Hill SA; Lewis SE; Ehle AL; Beyer CW; Moore RJ
Trans Am Neurol Assoc; 1979; 104():256-60. PubMed ID: 121949
[No Abstract] [Full Text] [Related]
10. [Reversible opening of the blood-brain barrier in the chemotherapy of malignant gliomas].
Heimberger K; Samec P; Podreka I; Binder H; Suess E; Reisner T; Deecke L; Steger G; Hiesmayr M; Dittrich C
Wien Klin Wochenschr; 1987 May; 99(11):385-8. PubMed ID: 3113082
[TBL] [Abstract][Full Text] [Related]
11. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
[TBL] [Abstract][Full Text] [Related]
12. [Intra-arterial infusion of high dose methotrexate therapy in recurrent gliomas].
Hayashi A; Kyuma Y
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1461-6. PubMed ID: 2117886
[TBL] [Abstract][Full Text] [Related]
13. [Blood-brain barrier opening microcirculation in human brain tumor].
Sato S; Toya S; Otani M
No To Shinkei; 1985 Feb; 37(2):109-13. PubMed ID: 2988587
[TBL] [Abstract][Full Text] [Related]
14. Osmotic blood-brain barrier disruption in the posterior fossa of the dog.
Neuwelt EA; Glasberg M; Diehl J; Frenkel EP; Barnett P
J Neurosurg; 1981 Nov; 55(5):742-8. PubMed ID: 6796658
[TBL] [Abstract][Full Text] [Related]
15. Technique of, and complications attributable to, repeated hyperosmotic blood-brain barrier disruption in dogs.
Culver B; Inzana K; Jones J; Troy G; Kroll R; Culver B; Jortner B
Am J Vet Res; 1998 Nov; 59(11):1503-10. PubMed ID: 9829415
[TBL] [Abstract][Full Text] [Related]
16. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans.
Siegal T; Rubinstein R; Bokstein F; Schwartz A; Lossos A; Shalom E; Chisin R; Gomori JM
J Neurosurg; 2000 Apr; 92(4):599-605. PubMed ID: 10761648
[TBL] [Abstract][Full Text] [Related]
17. [The effect on the tumor vessel permeability by hyperosmotic blood brain barrier disruption].
Miyagami M; Tazoe M; Kagawa Y; Tsubokawa T
No To Shinkei; 1988 Sep; 40(9):875-82. PubMed ID: 3142506
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology and toxicity of intracarotid adriamycin administration following osmotic blood-brain barrier modification.
Neuwelt EA; Pagel M; Barnett P; Glassberg M; Frenkel EP
Cancer Res; 1981 Nov; 41(11 Pt 1):4466-70. PubMed ID: 6796261
[TBL] [Abstract][Full Text] [Related]
19. [Intra-arterial ACNU, CDDP chemotherapy for brain metastases from lung cancer: comparison of cases with and without intra-arterial mannitol infusion].
Iwadate Y; Namba H; Saegusa T; Sueyoshi K
No Shinkei Geka; 1993 Jun; 21(6):513-8. PubMed ID: 8336809
[TBL] [Abstract][Full Text] [Related]
20. Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery.
Neuwelt EA; Maravilla KR; Frenkel EP; Rapaport SI; Hill SA; Barnett PA
J Clin Invest; 1979 Aug; 64(2):684-8. PubMed ID: 457877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
